Clinical trial NCT04830592 uses intravenous infusion to deliver an adenoviral vector producing a bispecific T cell activator (TAc) plus CXCL9/CXCL10/IFNa2 to kill tumor cells and stimulate immunity against the tumor cells53. This evidence concerns the gene CXCL9 and neoplasm.